BCL2 and plasma cell myeloma: In addition to MCL1-dependence, about 20% of myeloma cases, and notably those featuring t(11;14) translocations, are co-dependent from BCL2 deregulation and are thus responsive to BCL2-targeted therapy using venetoclax [47,48].